Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.

[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.

It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.

[4] A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates.

A phase I/II open label study in pediatric patients with a rare form of brain cancer, diffuse intrinsic pontine glioma, found improvement in overall survival compared to expected outcome.